Cart
sales@molnova.com
Home - Products - Cell Cycle/DNA Damage - c-Myc - MYCi975

MYCi975

CAS No. 2289691-01-4

MYCi975( NUCC-0200975 )

Catalog No. M22558 CAS No. 2289691-01-4

MYCi975 is an orally active inhibitor of MYC.MYCi975 inhibits P493-6, MV411,SK-N-B2 cells viability in an MYC-dependent manner(IC50s of 3.7, 3.9, 6.4 μM, respectively).The initial lead, MYC inhibitor 361 (MYCi361), suppressed in vivo tumor growth in mice, increased tumor immune cell infiltration, upregulated PD-L1 on tumors, and sensitized tumors to anti-PD1 immunotherapy. However, 361 demonstrated a narrow therapeutic index.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 267 In Stock
10MG 443 In Stock
25MG 737 In Stock
50MG 1017 In Stock
100MG 1377 In Stock
500MG 2673 In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    MYCi975
  • Note
    Research use only, not for human use.
  • Brief Description
    MYCi975 is an orally active inhibitor of MYC.MYCi975 inhibits P493-6, MV411,SK-N-B2 cells viability in an MYC-dependent manner(IC50s of 3.7, 3.9, 6.4 μM, respectively).The initial lead, MYC inhibitor 361 (MYCi361), suppressed in vivo tumor growth in mice, increased tumor immune cell infiltration, upregulated PD-L1 on tumors, and sensitized tumors to anti-PD1 immunotherapy. However, 361 demonstrated a narrow therapeutic index.
  • Description
    MYCi975 is an orally active inhibitor of MYC.MYCi975 inhibits P493-6, MV411,SK-N-B2 cells viability in an MYC-dependent manner(IC50s of 3.7, 3.9, 6.4 μM, respectively)[1].The initial lead, MYC inhibitor 361 (MYCi361), suppressed in vivo tumor growth in mice, increased tumor immune cell infiltration, upregulated PD-L1 on tumors, and sensitized tumors to anti-PD1 immunotherapy. However, 361 demonstrated a narrow therapeutic index. An improved analog, MYCi975 showed better tolerability.?
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    NUCC-0200975
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    c-Myc
  • Recptor
    MYC
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2289691-01-4
  • Formula Weight
    561.3
  • Molecular Formula
    C25H16Cl2F6N2O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:247 mg/mL (440.05mM)
  • SMILES
    Cn1nc(cc1-c1ccc(OCc2ccc(Cl)cc2)c(-c2ccc(Cl)c(c2)C(F)(F)F)c1O)C(F)(F)F
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Han H, et al. Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy. Cancer Cell. 2019 Nov 11;36(5):483-497.e15.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • APTO-253

    APTO-253 inhibits c-Myc expression, stabilizes G-quadruplex DNA, and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells. APTO-253 mediates anticancer activity through the induction of the KLF4 tumor suppressor.APTO-253 (5 μM) induces KLF4 expression and enhances apoptosis induced by NSC 119875 in both SKOV3 and OVCAR3 cells.

  • MYCi361

    MYCi361 is an inhibitor of MYC (binding to MYC with Kd of 3.2 μM). MYCi361 is a small-molecule MYC inhibitors that inhibits the viability of MYC-dependent cancer cells including prostate cancer (MycCaP, LNCaP, and PC3), leukemia (MV4-11), lymphoma (HL-60 and P493-6), and neuroblastoma (SK-N-B2) with low-micromolar IC50 values.

  • KJ-Pyr-9

    KJ-Pyr-9 is a novel small-molecule inhibitor of c-Myc (Kd=6.5 ± 1.0 nM).

Sign In Join Free